Incyte | INCY - Interest Income


Incyte reported $30.75M in Interest Income for its fiscal quarter ending in December of 2025.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.25M 1M Sep/2025
Agios Pharmaceuticals USD 13.37M 1.14M Sep/2025
Alnylam Pharmaceuticals USD 28.68M 1.19M Sep/2025
BioCryst Pharmaceuticals USD -0.13 3.59M Dec/2024
Biogen USD 31.6M 700K Sep/2025
BioMarin Pharmaceutical USD 17.85M 973K Sep/2025
Eli Lilly USD 65M 25M Sep/2025
Exelixis USD 15.92M 867K Sep/2025
Gilead Sciences USD 88M 15M Sep/2025
Incyte USD 30.75M 3.97M Dec/2025
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
MacroGenics USD 1.53M 114K Sep/2025
Merck USD 96M 27M Sep/2025
Moderna USD 73M 8M Sep/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD 0.62 156M Sep/2025
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 175.1M 300K Sep/2025
Sarepta Therapeutics USD 8.38M 1.24M Sep/2025
Ultragenyx Pharmaceutical USD 5.86M 69K Sep/2025
Vertex Pharmaceuticals USD 125.7M 3.3M Sep/2025